Login / Signup

Escape Velocity-the Launch of Microbiome Therapies.

Brendan J KellyJennie H KwonMichael H Woodworth
Published in: The Journal of infectious diseases (2024)
Food and Drug Administration approval of the first microbiome therapies represents a true expansion the treatment paradigm for Clostridioides difficile but raises new questions about the future role of fecal microbiota transplantation. The authors outline the advances in microbiome therapeutic development that have addressed fecal microbiota transplantation's (FMT's) inherent limitations of safety and scalability. The authors also suggest that as microbiome therapeutic development continues for other indications, FMT will likely remain a necessary model of human microbiota dynamics for translational research.
Keyphrases
  • drug administration
  • endothelial cells
  • clostridium difficile
  • cell therapy
  • induced pluripotent stem cells
  • mesenchymal stem cells
  • climate change
  • combination therapy
  • pluripotent stem cells